INTRODUCTION
Adenocarcinoma of the prostate is treated with androgen deprivation therapy (ADT) in men with metastatic disease and in many with nonmetastatic disease who present with biochemical recurrence, defined as increasing prostate-specific antigen (PSA) after localized therapy with prostatectomy and/or radiotherapy.
1 Subsequent disease progression in the setting of castrate levels of testosterone on ADT, as manifested by increasing PSA or radiographic progression in bone or soft tissue, signals the development of castrationresistant prostate cancer (CRPC).
2 Several new therapies have been approved recently to treat metastatic CRPC, including agents that target the androgen receptor signaling pathway (enzalutamide, abiraterone acetate plus prednisone), chemotherapy (cabazitaxel after previous treatment with docetaxel), immunotherapy (sipuleucel-T) and, for men with symptomatic bone metastatic CRPC but no known visceral disease, radioisotope therapy with radium-223 dichloride. [3] [4] [5] [6] [7] [8] [9] There is currently no approved therapy for nonmetastatic CRPC, and there is no evidence that the addition of bicalutamide to ongoing ADT has an impact on the outcome of metastatic CRPC.
Initial treatment of CRPC typically includes adding a second-line hormonal agent such as an antiandrogen, most commonly bicalutamide, to ADT. 1 ,2 Yet the practice of adding bicalutamide to ADT in the setting of castration resistance is based on single-arm studies in a modest number of men that suggested limited benefit lasting no more than 3 to 6 months. [10] [11] [12] [13] [14] Furthermore, bicalutamide can function as an androgen receptor partial agonist and can fuel disease progression, 15 particularly in the setting of androgen receptor overexpression frequently observed in CRPC. 16 This agonist activity becomes clinically apparent when PSA declines upon discontinuation of bicalutamide, a phenomenon known as antiandrogen withdrawal response. [17] [18] [19] Enzalutamide is an androgen receptor inhibitor that binds to the androgen receptor in the same way as bicalutamide but with higher affinity. Preclinical studies demonstrated that enzalutamide, unlike bicalutamide, lacks agonist activity at the wild-type androgen receptor 20, 21 and impairs nuclear translocation of the androgen receptor and its binding to DNA, which leads to reduced expression of androgen-dependent genes. 21, 22 Two large multinational phase III trials in men with metastatic CRPC demonstrated improved overall survival over placebo in both prechemotherapy ( 3 ) settings. The demonstrated clinical benefit of enzalutamide in patients with metastatic CRPC and its superior activity in suppressing androgen receptor signaling in preclinical models suggested that enzalutamide might confer clinical benefit compared with bicalutamide in patients with either nonmetastatic or metastatic CRPC who would ordinarily be treated with the addition of bicalutamide.
PATIENTS AND METHODS

STRIVE (Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in
Men With Prostate Cancer) was a multicenter, randomized, double-blind phase II trial of enzalutamide versus bicalutamide in men with nonmetastatic or metastatic CRPC. The review boards of all participating institutions approved the study, which was conducted according to the provisions of the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonization. All patients provided written informed consent to participate in the study.
Study Participants
Enrolled men had histologically or cytologically confirmed adenocarcinoma of the prostate, serum testosterone level # 50 ng/dL (1.73 nmol/L), and progressive disease despite ADT. Disease progression was defined as at least one of the following three criteria: PSA progression ($ 2 increasing PSA values with an interval of $ 1 week between determinations and PSA doubling time # 10 months if the central laboratory screening PSA was $ 2 and , 5 ng/mL), soft-tissue disease progression, or bone disease progression. Key exclusion criteria included prior disease progression while receiving bicalutamide, prior chemotherapy, or radiation for distant metastasis; systemic corticosteroids for prostate cancer; and history of seizure. A complete list of inclusion and exclusion criteria is provided in Appendix Table A1 (online only) .
Patients were randomly assigned 1:1 to enzalutamide (160 mg per day as four 40-mg capsules plus one placebo capsule) or bicalutamide (50 mg per day as one capsule plus four placebo capsules), stratified by disease stage (M0/N0, M0/N1, or M1). M0/N0 signified absence of bone metastases on bone scan and absence of soft-tissue disease; M0/N1 signified absence of bone metastases on bone scan and distant soft-tissue metastases but with nodal metastases below the aortic bifurcation; and M1 signified bone metastases on bone scan or soft-tissue metastases (including nodal) above the aortic bifurcation. ADT was maintained throughout the study, and concurrent use of bisphosphonates and denosumab was permitted. Patients were to continue receiving study drug at least until confirmed PSA or radiographic progression or until an adverse event that would lead to undue risk if dosing had continued.
Study End Points
The primary end point was progression-free survival (PFS), defined as the time from random assignment to a progression event or death as a result of any cause. Progression events included PSA progression per Prostate Cancer Clinical Trials Working Group 2 guidelines 23 or investigator-assessed radiographic progression (Appendix Table A2 , online only). Key secondary end points included time to PSA progression, PSA response of $ 50% (defined as $ 50% reduction in PSA at any postbaseline assessment), and radiographic progression-free survival (rPFS) for patients with metastatic disease only. Other end points included best overall softtissue response (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] 24 ) in metastatic patients with measurable disease at screening, time to a 10-point or greater decline of the global score of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, and PSA response of $ 90% (defined as $ 90% reduction in PSA at any postbaseline assessment). Definitions and associated analyses for all end points are detailed in Appendix Table A2 .
Statistical Analysis
The intent-to-treat population included all randomly assigned patients. A minimum of 231 PFS events provided 90% power to detect a hazard ratio (HR) of 0.65 based on a two-sided log-rank test with a significance level of 0.05. Time-to-event end points, including the primary end point of PFS as well as time to PSA progression and rPFS, were compared between the two treatment arms by using a two-sided log-rank test stratified by disease stage (nonmetastatic [M0N0 and M0N1] or metastatic) where applicable. Kaplan-Meier curves and medians were calculated for these end points, and HRs were estimated by using a Cox regression model stratified by disease stage where applicable. A twosided Cochran-Mantel-Haenszel test was used to compare PSA response rates for enzalutamide and bicalutamide. Hypothesis testing for primary and key secondary end points was performed with an overall significance level of 0.05 and multiple testing was accounted for. The safety population was defined as all randomly assigned patients who received at least one dose of study drug. Safety data were not adjusted for time on study drug.
RESULTS
Patients and Treatment Duration
A total of 396 patients at 62 sites in the United States were randomly assigned between August 2012 and March 2014 to receive enzalutamide (n = 198) or bicalutamide (n = 198). Figure 1 shows the flow of patients through the study. Baseline demographic and disease characteristics were well balanced between groups (Table 1 and Appendix Table A3 [online only]). Median time on treatment was 14.7 months for the enzalutamide group compared with 8.4 months for the bicalutamide group. More patients in the enzalutamide group than in the bicalutamide group received $ 12 months of treatment (68% v 35%) and continued on study treatment at the February 9, 2015, data cutoff date (53% v 20%).
Efficacy
Primary end point. All efficacy analyses were conducted on the intent-to-treat population unless otherwise stated. Treatment with enzalutamide reduced the risk of progression or death by 76% compared with bicalutamide (HR, 0.24; 95% CI, 0.18 to 0.32; P , .001). Median PFS was 19.4 months with enzalutamide and 5.7 months with bicalutamide (Fig 2A and Table 2 ). The treatment effect of enzalutamide on PFS was consistently favorable across all prespecified subgroups (Fig 2B) , including disease state (nonmetastatic v metastatic) at study entry. In patients with nonmetastatic CRPC, median PFS was not reached with enzalutamide compared with 8.6 months with bicalutamide (HR, 0.24; 95% CI, 0.14 to 0.42). In patients with metastatic CRPC, median PFS was 16.5 months with enzalutamide and 5.5 months with bicalutamide (HR, 0.24; 95% CI, 0.17 to 0.34; Table 2 ).
Key secondary end points. Analyses of all key secondary end points found enzalutamide to be significantly superior to bicalutamide (Table 2) . Enzalutamide was associated with a decrease in the risk of radiographic progression or death compared with bicalutamide in both metastatic and nonmetastatic disease: 68% (HR, 0.32; 95% CI, 0.21 to 0.50; P ,.001; Fig 2C and Table 2 ) and 76% (HR, 0.24; 95% CI, 0.10 to 0.56; Table 2), respectively. The median rPFS in those with metastatic disease was not reached with enzalutamide compared with 8.3 months with bicalutamide.
Enzalutamide was associated with an 81% reduction in the risk of PSA progression (HR, 0.19; 95% CI, 0.14 to 0.26; P , .001; Fig 3A) . Median time to PSA progression was not reached with enzalutamide compared with 8.3 months with bicalutamide (Table 2 ). Among patients with at least one postbaseline PSA value, a PSA response $ 50% was achieved by 156 (81%) of 192 patients in the enzalutamide group compared with 61 (31%) of 195 patients in the bicalutamide group (P , .001; Fig 3B) . In addition, secondary outcomes favored enzalutamide in both the nonmetastatic and metastatic subgroups (Table 2) .
Other end points. Among patients with measurable soft-tissue metastatic disease at baseline, 21 (60%) of 35 patients in the Among patients with at least one postbaseline PSA value, a PSA response of $ 90% was achieved by 124 (65%) of 192 patients treated with enzalutamide compared with 17 (9%) of 195 patients treated with bicalutamide (P , .001; Fig 3B) .
Safety
Adverse events are summarized in Tables 3 and 4 . Serious adverse events, grade $ 3 adverse events, and adverse events resulting in death were reported at similar rates in both treatment groups. Among the common adverse events (ie, occurring in $ 10% of patients in either treatment group, with a difference between groups of $ 2%), those reported more frequently with enzalutamide than with bicalutamide included fatigue, back pain, hot flashes, falls, hypertension, dizziness, and decreased appetite. Common adverse events reported more frequently with bicalutamide than with enzalutamide included constipation, diarrhea, anemia, and urinary tract infection. One patient in the enzalutamide group experienced a seizure; this patient had a previously undisclosed history of multiple seizures before study entry.
DISCUSSION
STRIVE is the first randomized, double-blind, head-to-head trial of bicalutamide versus enzalutamide in men with nonmetastatic or metastatic CRPC. Enzalutamide significantly reduced the risk of disease progression or death by 76% compared with bicalutamide, and the benefit of enzalutamide over bicalutamide was robust, with a more than 1-year prolongation of median PFS. Although the Type of progression at study entry -PSA progression only
Type of progression at study entry -radiographic progression with or without PSA progression median PFS for enzalutamide of 19.4 months exceeded study design projections, the limited 5.7-month benefit of bicalutamide was expected. The benefit associated with enzalutamide was seen across all subgroups, including disease state (nonmetastatic and metastatic) at study entry. The superiority of enzalutamide relative to bicalutamide was also observed across all key secondary end points, including time to PSA progression and PSA response. Although it is unknown whether earlier treatment with enzalutamide could lead to resistance to subsequent therapies, these data suggest that enzalutamide should replace bicalutamide in the treatment of men with CRPC.
In practice, bicalutamide 50 mg per day is commonly used for patients for whom ADT has failed despite the lack of randomized clinical trials showing a durable or widely experienced clinical benefit in the setting of castration resistance. The original approval in Europe of bicalutamide 150 mg per day for locally advanced prostate cancer was based on the results of the Early Prostate Cancer trial, which found that bicalutamide 150 mg plus standard therapy significantly reduced the risk of progressive disease in patients with early prostate cancer compared with standard care alone. 25 Bicalutamide 50 mg per day was approved for use in the United States on the basis of a trial of men with hormone-naïve metastatic disease in which flutamide served as comparator; both were administered in combination with luteinizing hormonereleasing hormone analog therapy, 26 and no differences in overall survival or time to progression were reported. 27 In the absence of approved therapies, the use of bicalutamide migrated to the treatment of castration-resistant disease. However, men with CRPC treated with bicalutamide second-line hormonal therapy, even at a higher dose of 150 mg per day, have experienced relatively short response durations, 14 which may result from the partial agonist activity of bicalutamide coupled with overexpression of the androgen receptor, a primary mechanism in the development of castration-resistant disease. 16 Enzalutamide overcomes the limitations of bicalutamide, such as suboptimal clinical results resulting from low affinity for the androgen receptor at which bicalutamide exerts partial agonist activity. Enzalutamide has a 10-fold greater affinity for the androgen receptor than bicalutamide, lacks agonist activity unlike bicalutamide, and now in two prospective, randomized blinded studies has shown an overall survival benefit in men with metastatic CRPC. 3, 4, 21 The STRIVE study enrolled patients earlier in the course of the disease, before resistance to bicalutamide therapy had developed and, in some patients, before metastatic disease had developed. The stabilization of CRPC by enzalutamide in the study overall, as demonstrated by a prolongation in PFS, was consistently observed in both the nonmetastatic and metastatic subgroups. This is the first study to indicate a benefit of enzalutamide in patients with nonmetastatic CRPC. The phase III PROSPER (NCT02003924; Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer) trial is now evaluating the impact of enzalutamide versus placebo on metastasis-free survival in patients with nonmetastatic CRPC.
Data from the STRIVE study suggest that patients with nonmetastatic CRPC in the enzalutamide arm did better than those with metastatic CRPC in terms of duration of stable disease (median PFS www.jco.org not reached v 16.5 months) and longer time to PSA progression and improved PSA response. These findings might be expected on the basis of the smaller tumor burden in the nonmetastatic subgroup, and they support the importance of early disease detection. For men with measurable soft-tissue metastatic disease at study entry in STRIVE, meaningful tumor shrinkage (overall response rates by RECIST 1.1) with enzalutamide was demonstrated in the majority of patients (60%) compared with 14% in the bicalutamide arm. The soft-tissue response rate observed in STRIVE is consistent with the 59% response rate observed with enzalutamide in the PREVAIL study of chemotherapy-naïve metastatic CRPC.
Enzalutamide and bicalutamide were generally well tolerated in this study, with enzalutamide demonstrating a safety profile consistent with that reported in two large placebo-controlled phase III trials in metastatic CRPC. 3, 4 In STRIVE, both drugs were associated with reports of fatigue and hot flash adverse events, although to a greater extent with enzalutamide, which is consistent with more effective androgen receptor signaling inhibition without a significant difference in quality of life as assessed by the FACT-P questionnaire. A slightly higher proportion of patients with hypertension entered STRIVE in the enzalutamide group compared with the bicalutamide group (74.2% v 68.7%). Adverse events of hypertension were reported by 12.2% and 5.1% of patients in the enzalutamide and bicalutamide groups, respectively, and were reported at grade 3 (systolic blood pressure $ 160 mm Hg or diastolic blood pressure $ 100 mm Hg) in 5.1% versus 1.5% of patients, respectively.
A limitation of this study was that it did not address the benefit of sequential therapy with bicalutamide followed by enzalutamide. However, the suggestion from the cross-trial comparisons mentioned 28 The ongoing phase III PROSPER study of enzalutamide versus placebo in patients with nonmetastatic CRPC is evaluating this question.
Data from enzalutamide-treated patients across the CRPC spectrum suggest a disease continuum with a longer time to disease progression in those treated with enzalutamide earlier in the disease course of CRPC. Median time to PSA progression with enzalutamide was 8.3 months in men with late-stage metastatic CRPC treated after chemotherapy in AFFIRM, 11.2 months in men with metastatic CRPC treated before chemotherapy in PREVAIL, and 19.4 months in men with metastatic CRPC for whom bicalutamide therapy had not failed in TERRAIN; it was not reached (lower bound of 95% CI, 19.4 months) in men with nonmetastatic or metastatic CRPC for whom bicalutamide therapy had not failed in STRIVE (Appendix Table A4 , online only). New classifications of disease states within CRPC based on sensitivity and resistance to androgen receptor inhibition rather than the absence or presence of radiographically evident metastases or history of chemotherapy use might better guide treatment and prognosis because the findings from STRIVE suggest that CRPC may be addressed without regard to these latter factors.
In conclusion, the improved clinical outcomes with enzalutamide compared with bicalutamide in patients with nonmetastatic or metastatic CRPC in the STRIVE study add to the growing body of evidence supporting the use of enzalutamide in patients across a broad CRPC spectrum. Progression-free survival* Progression-free survival, the primary end point, was defined as the time from random assignment to the earliest objective evidence of PSA progression, radiographic disease progression, or death on study (death as a result of any cause up to and including 30 days after treatment discontinuation), whichever occurred first. PSA progression was defined according to PCWG2 guidelines. The PSA progression date was defined as the date that a $ 25% increase in PSA with an absolute increase of $ 2 ng/mL above the nadir (or baseline for patients with no PSA decline at week 13) was documented, which was confirmed by a second consecutive value obtained at least 3 weeks later. Radiographic disease progression included soft-tissue disease progression as defined by RECIST 1.1 and bone disease progression per PCWG2 guidelines. Bone disease progression was defined as the appearance of two or more new bone lesions on bone scan. Bone disease progression at or before week 13 required a consecutive confirmatory bone scan at least 5 weeks later with at least two additional bone lesions. If bone disease progression was confirmed, the date of bone disease progression would be the date of the initial scan suggesting progression. Soft-tissue disease progression did not require confirmation. All radiographic assessments were locally based. Generally, patients who had not progressed or died by the data cutoff date were censored on the date of the last available PSA or radiographic assessment. A two-sided log-rank test stratified by disease stage at study entry (M0 or M1) was used to compare progression-free survival between the treatment groups (enzalutamide and bicalutamide). Time to PSA progression † Time to PSA progression was defined as the time from random assignment to the earliest evidence of PSA progression per PCWG2 guidelines. The PSA progression date was defined as the date that a $ 25% increase in PSA with an absolute increase of $ 2 ng/mL above the nadir (or baseline for patients with no PSA decline at week 13) was documented, which was confirmed by a second consecutive value obtained at least 3 weeks later. A log-rank test stratified by disease stage at study entry (M0 or M1) was used to compare the time to PSA progression between the treatment groups. PSA response † ‡ Confirmed PSA responses, defined as $ 50% † and $ 90% ‡ reductions in PSA from baseline at any postbaseline assessment, were calculated by treatment group for patients with a baseline PSA value and at least one postbaseline PSA value. Confirmation of these PSA responses was required at a consecutive assessment obtained at least 3 weeks later. A Cochran-Mantel-Haenszel mean score test stratified by disease stage at study entry (M0 or M1) was used to compare the response rates between the treatment groups. Radiographic progression-free survival † ‡ Radiographic progression-free survival was defined as the time from randomization to the first objective evidence of radiographic disease progression or death on study (death as a result of any cause up to and including 30 days after treatment discontinuation), whichever occurred first. Radiographic disease progression included soft-tissue disease progression as defined by RECIST 1.1 and bone disease progression per PCWG2 guidelines. Bone disease progression was defined as the appearance of two or more new bone lesions on bone scan. Bone disease progression at or before week 13 required a consecutive confirmatory bone scan at least 5 weeks later with at least two additional bone lesions. If bone disease progression was confirmed, the date of bone disease progression would be the date of the initial scan suggesting progression. Soft-tissue disease progression did not require confirmation. Generally, patients who had not progressed or died by the data cutoff date were censored on the date of the last available radiographic assessment. An unstratified log-rank test was used to compare radiographic progression-free survival between the treatment groups separately for M1 patients † and M0 patients ‡. Functional Assessment of Cancer Therapy-Prostate (FACT-P) ‡ FACT-P is a multidimensional, self-reported quality-of-life instrument specifically designed for use with prostate cancer. It consists of 27 core items that assess patient function in four domains-physical, social/family, emotional, and functional well-being-supplemented by 12 site-specific items to assess for prostate cancer symptoms. Each item is rated on a Likert-type scale of 0 to 4 and then combined to produce subscale scores for each domain as well as a global quality-of-life score (higher scores represent better quality of life). Time to degradation of FACT-P was defined as the time from random assignment to the date of the first assessment with at least a 10-point decrease from baseline in the global score. A log-rank test stratified by disease stage at study entry (M0 or M1) was used to compare the time to degradation of FACT-P between the treatment groups. Best overall soft-tissue response ‡ The best overall soft-tissue response was assessed by using RECIST 1.1 and was defined as a best overall soft-tissue response of CR or PR. Only patients with measurable (at least one target lesion) M1 soft-tissue disease at screening were included in the analysis. The proportion of patients with objective response (CR or PR) were compared between the treatment groups with an unstratified Cochran-Mantel-Haenszel mean score test.
Abbreviations: CR, complete response; M0, no distant metastasis (could have regional nodal metastasis); M1, presence of distant metastasis; PCWG2, Prostate Cancer Clinical Trials Working Group 2; PR, partial response; PSA, prostate-specific antigen; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1. *Primary end point.
†Key secondary end point. ‡Other prespecified secondary or exploratory end point. 
